| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S88514-2mg促销 |
97% | ￥910.00 ￥720.00 |
货期：3-5天 | - | - | - | - |
|
S88514-5mg促销 |
97% | ￥1590.00 ￥1270.00 |
货期：3-5天 | - | - | - | - |
|
S88514-10mg促销 |
97% | ￥2590.00 ￥2070.00 |
8 | - | - | - | - |
|
S88514-25mg促销 |
97% | ￥5560.00 ￥4440.00 |
4 | - | - | - | - |
|
S88514-50mg促销 |
97% | ￥10300.00 ￥8230.00 |
2 | - | - | - | - |
|
S88514-100mg促销 |
97% | ￥15700.00 ￥12600.00 |
3 | - | - | - | - |
|
| 产品描述： | INCB-057643 is a novel, orally bioavailable BET inhibitor. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | BET;Apoptosis; EpigeneticReaderDomain | ||||||||||||||||||||
| 体外研究： | INCB-057643 is a novel, orally bioavailable BET inhibitor. INCB-057643 inhibits binding of BRD2/BRD3/BRD4 to an acetylated histone H4 peptide in the low nM range, and is selective against other bromodomain containing proteins. In vitro analyses show that INCB-057643 inhibits proliferation of human AML, DLBCL, and multiple myeloma cell lines, with a corresponding decrease in MYC protein levels. Cell cycle analyses indicate that G1 arrest and a concentration-dependent increase in apoptosis are seen within 48 hours of treatment with INCB-057643 | ||||||||||||||||||||
| 体内研究： | Production of several cytokines, including IL-6, IL-10 and MIP-1α, is repressed by INCB-057643 in human and mouse whole blood stimulated ex vivo with LPS. Oral administration of INCB-057643 results in significant anti-tumor efficacy in xenograft models of AML, myeloma, and DLBCL. Additionally, combining INCB-057643 with standard of care agents used for the treatment of DLBCL including rituximab and bendamustine results in enhanced anti-tumor efficacy relative to that achieved with single agent therapies at doses that are well tolerated | ||||||||||||||||||||
| 参考文献： | 1. Matthew C. Stubbs, et al. Abstract 5071: Preclinical characterization of the potent and selective BET inhibitor INCB057643 in models of hematologic malignancies. AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5071. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20°C | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
